Drug safety remains a top global public health concern. An increase in the number of data sources available has increased the complexity of pharmacovigilance operations so the US FDA has created draft guidance focusing on optimizing drug safety data for well-characterized medicines. However to date no data demonstrating changes in reports have been presented. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.